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The polyphenol piceatannol has shown inhibition against tyrosine and serine/threonine kinases. Whether piceatannol also exerts
activity on the mammalian target of rapamycin (mTOR), a kinase involved in growth control of eukaryotic cells, is not known. In
this study, we tested the eﬀects of piceatannol on proliferation of androgen-dependent (AD) LNCaP and androgen-independent
(AI) DU145 and PC-3 prostate cancer (CaP) cells. Suppression of AD and AI CaP cell growth by piceatannol was accompanied by
cell cycle blockade in G1/S and S phases for LNCaP and PC-3 and induction of apoptosis in DU145 cells. Induction of apoptosis
by piceatannol in DU145 cells was evident by reduced expression of poly(ADP-ribose) polymerase (PARP), cleavage of caspase 3
and apoptosis inducing factor AIF, and an increase in cytochrome c. The apoptotic changes occurred in concordance with DNA
damage, supported by increased phosphorylated histone H2AX. Immunoblot analyses showed that exposure of diﬀerent-stage
CaP cells to piceatannol also resulted in cell-type-speciﬁc downregulation of mTOR and its upstream and downstream eﬀector
proteins, AKT and eIF-4E-BP1. We propose that the observed AKT and mTOR changes are new targets of piceatannol possibly
contributing to its inhibitory activities on proliferation of CaP cells.
1.Introduction
Piceatannol (3,3 ,4,5 -tetrahydroxy-trans-stilbene) is a poly-
phenol found in food sources such as grapes, berries, pean-
uts,andsugarcane[1–4].WhenﬁrstisolatedfromEuphorbia
lagascae, piceatannol was found to exhibit antileukemic
activity [5]. Subsequent experiments showed that piceatan-
nol displays antioxidant [6, 7], anti-inﬂammatory [8, 9],
and anticarcinogenic properties [10–12]. In cell model
studies, piceatannol prevented TNF-induced NFκBa c t i v a -
tion [9, 13, 14], by controlling the oxidoreductive status
of cysteine-179 in IKKβ [4]. Suppression of lung metas-
tasis occurred in Lewis-lung-carcinoma-bearing mice fed
piceatannol-fortiﬁed diet [15].
Mechanistically, piceatannol has been investigated as an
inhibitor for tyrosine kinases, including Syk [16–18], FAK
[19, 20], and serine/threonine kinases [21]. Furthermore,
piceatannol is also used to explore the role of the mito-
chondrial F0F1-ATPase [22, 23], in relation to apoptosis.
Recent studies show that piceatannol inhibits proliferation
and induces cell cycle arrest and apoptosis in DU145 CaP
cells [24–26] and that the anticellular eﬀects of piceatan-
nol are mediated by suppression of the cyclin-dependent
protein kinase activities (CDKs) [26]. These results suggest
that piceatannol might have chemopreventive potential for
CaP.
ThemTORisaserine/threonine proteinkinasethatplays
a crucial role in sensing the availability of nutrients for
control of cell growth, generally conferring survival beneﬁts
[27, 28]. Since mTOR is frequently deregulated in cancer and
because, as mentioned, piceatannol acts as a potent kinase
inhibitor, it is of interest to determine whether piceatannol
might aﬀect mTOR activity/expression and in turn disrupt
mTOR-mediated signaling events.2 ISRN Urology
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Figure 1: Eﬀects of piceatannol on colony formation and cell proliferation in LNCaP, DU145, and PC-3 CaP cells. (a) Control of
clonogenicity by piceatannol. Cells were plated in 6-well tissue culture dishes at 2,000cells/mL and treated with increasing concentrations
of piceatannol (0, 1, 5, 10, 25, and 50μM). After 1 week, colonies were stained with 1.25% crystal violet and quantiﬁed by measuring the
absorbance at 595nm. Dose-dependent suppression of colony formation by piceatannol was expressed as a percentage of control (set as
100%). Values are expressed as mean ± SD for three separate experiments. The symbol represents statistical signiﬁcance:
∗P ≤ 0.001. (b)
Control of cell growth by piceatannol. Cells were treated with increasing doses of piceatannol (0, 10, and 25μM). The cell numbers were
determined at 72h using a hemocytometer. The bars show dose-dependent suppression of growth, expressed as a percentage of control (set
as 100%). Values are expressed as mean ± SD for three experiments. The symbol represents statistical signiﬁcance:
∗P ≤ 0.001.
In this study, we tested the hypothesis that piceatannol
controlsproliferationofbothandrogen-dependent(AD)and
rogen-independent(AI)CaPcellsbytargetingtheexpression
of mTOR. We also determined whether piceatannol disrupts
the mTOR signaling pathway in CaP cells by eliciting
changes in mTOR and its upstream and downstream eﬀector
proteins: mTOR, protein kinase AKT, initiation factor eIF-
4E regulatory binding protein eIF-4E-BP1, and ribosomal
protein p70 S6 kinase. We found that piceatannol suppressed
AD and AI CaP cell proliferation and that its growth
inhibitory activity was accompanied by reduced expression
of mTOR and its key eﬀectors AKT and eIF4EBP-1.
2.MaterialsandMethods
2.1.Reagents. PiceatannolwasobtainedfromA.G.Scientiﬁc,
Inc. (San Diego, CA). The translational control sample kit
was from Cell Signaling Technology, Inc. (Beverly, MA).
The primary antibodies for cyclins D1 and E, CDKs 2
and 6, AIF, caspase 3, cytochrome c, actin, and secondary
antibodies were from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA). The antibody against phosphorylated histone
H2AX (Ser139) was from Upstate Biotechnology Inc. (Lake
Placid, NY). The antibodies for PARP were from Biomol
International, L.P. (Plymouth Meeting, PA). Fetal bovine
serum (FBS), RPMI 1640, penicillin, and streptomycin were
from Cellgro, Inc (Herndon, VA). All other chemicals and
solvents used were of analytical grade.
2.2. Cell Culture, Colony Formation, and Proliferation Assays.
Human LNCaP, DU145, and PC-3 cells were obtained from
the American Tissue Culture Collection (Manassas, VA) and
cultured in RPMI 1640 supplemented with penicillin, strep-
tomycin, and 10% heat-inactivated FBS, as described [29].
Piceatannol was dissolved in dimethyl sulfoxide (DMSO)
and added to the culture media at the speciﬁed dose. Colony
formation assay was performed as detailed [30]. Brieﬂy,
cells (800–2000cells/mL, 2mL/well in 6-well plates) wereISRN Urology 3
incubated with increasing doses of piceatannol. Colonies
were stained with 1.25% crystal violet, extracted with 10%
acetic acid, and quantiﬁed by spectrometry at 595nm. The
experiments were performed in triplicate. For cell prolifer-
ation assays, cells were seeded in 6-well plates at a density
of 1 × 105 cells/mL for LNCaP cells and 5 × 104 cells/mL
for DU145 and PC-3 cells. Following treatment, control and
treated cells were assayed by trypan blue exclusion using a
hemocytometer [29]. Harvested cells were washed with PBS
a n ds t o r e da t−80◦C for subsequent biochemical analyses.
2.3. Cell Cycle Analysis. Cells were treated with 0, 10, and
25μM piceatannol for 72h, washed with PBS, and stained
with 1.0μg/mL DAPI (Sigma Chemical Co., St. Louis, MO).
Cell cycle phase distribution was assayed by ﬂow cytometry
[31, 32]. MultiCycle software program from Phoenix Flow
Systems(SanDiego,CA)wasusedtodeconvolutethecellular
DNA histograms and quantify the percentage of cells in the
G1,S ,a n dG 2M phases. Induction of apoptosis was also
assayed by ﬂow cytometry, as the sub-G1peak [31, 32].
2.4. Preparation of Whole-Cell Extracts and Western Blot
Analysis. Cells were collected and lysed in ice-cold RIPA
buﬀer, which contained 50mM Tris, pH 7.4, 150mM
NaCl, 1mM EDTA, 1% Triton X-100, 1% deoxycholate,
0.1% SDS, 1mM dithiothreitol, and 10μL/mL protease
inhibitorcocktailfromSigma-AldrichCorp.(St.Louis,MO).
Protein concentrations of cell lysates were determined by
coomassie protein assay kit (Pierce, Rockford, IL) using
bovineserumalbuminBSAasthestandard.Forimmunoblot
analysis, lysates containing 10μg of protein were separated
by 10% SDS-gel electrophoresis, followed by transfer to
nitrocellulose membranes and blocked with TBST buﬀer
(10mM Tris, pH 7.5, 100mM NaCl, and 0.05% Tween 20)
containing 3% nonfat dried milk. The blots were incubated
with speciﬁc primary antibodies, followed by secondary
antibodies. Immunoreactivity was detected by enhanced
chemiluminescence (ECL) using the instructions provided
by the manufacturer (Kirkegaard & Perry Laboratories, Inc.,
Gaithersburg, MD). The expression of actin was used as
loadingcontrol.Theintensityofthespeciﬁcimmunoreactive
bands was densitometrically quantiﬁed and expressed as a
ratio relative to the expression of actin.
2.5. Data Analysis. The results were expressed as mean ±
standard deviation (SD). One-way ANOVA and Student’s t-
test were used to determine the signiﬁcance of diﬀerences in
measured variables between control and piceatannol-treated
cells. Statistical signiﬁcance was set at P ≤ 0.001.
3. Results
3.1. Piceatannol-Inhibited Clonogenicity and Proliferation in
CaP Cells. In previous studies by Kim and coworkers,
DU145 cells maintained in DMEM/F12 culture media sup-
plemented with 1% charcoal-treated FBS were followed by
24h serum deprivation and then treatment by piceatannol;
exposure to the polyphenol inhibited cell proliferation and
induction of apoptosis [25]. It was of interest to ascertain
whether piceatannol exerts a similar antiproliferative activity
in CaP cells representing diﬀerent stages of disease pro-
gression without prior serum depletion. Androgen-receptor-
(AR)-positive hormone-responsive LNCaP and AR-negative
hormone-nonresponsive DU145 and PC-3 CaP cells were
exposed to 0, 1, 5, 10, 25, and 50μM piceatannol, and eﬀects
on colony formation were determined. The addition of
>10μM piceatannol caused 50% suppression in foci forming
ability in all three cell lines tested (Figure 1(a)). Similarly,
as assayed by trypan blue exclusion, a dose-dependent
inhibition of proliferation was observed in the three cell
lines treated for 72h with 0, 10, and 25μM piceatannol
(Figure 1(b)).
3.2. Piceatannol-Induced Cell Cycle Arrest and Apoptosis in
CaP Cells. The nature of growth suppression by piceatannol
was next studied by measuring eﬀects on cell cycle distribu-
tion by ﬂow cytometry. Exposure to piceatannol resulted in
cell-type-dependent changes: (i) LNCaP cells showed G1/S
arrest, evident by an increase in the G1 cell population and
a corresponding diminution in S phase cells (Figure 2(a)).
(ii) As previously noted [25, 26], a signiﬁcant induction of
apoptosis occurred in DU145 cells (Figure 2(a)), although,
without altering cell cycle phase transition. (iii) S phase
accumulation, concomitant with reduction in percentage of
G1 cells, was observed in PC-3 cells (Figure 2(a)).
The diﬀerential cell cycle eﬀects elicited by piceatannol
in LNCaP and PC-3 cells prompted us to assess the changes
on the expression of cell cycle regulatory proteins by western
blot analysis. As cyclins D1and E and CDK2/CDK6 play a
pivotal role in controlling the cells entry from G1 into the S-
phase, the changes on their expression were ﬁrst measured.
In LNCaP cells, increased cyclin D1 but suppressed cyclin
E expression with relative low to undetectable expression
of CDK2 and CDK6 was found in piceatannol-exposed
cells (Figure 2(b)), in partial support of the G1 cell arrest
(Figure 2(a)). For PC-3 cells, a dose-dependent reduction in
cyclin D1/CDK6/CDK2 and induction of cyclin E expres-
sion were observed following treatment by piceatannol
(Figure 2(b)), consistent with an increase in S paralleled by
ad e c r e a s ei nG 1 phase transition (Figure 2(a)).
To corroborate induction of apoptosis in piceatannol-
exposed DU145 cells (Figure 2(a)), the expression of several
apoptosis-relatedgeneswasassayed.LevelsofPARPandpro-
caspase 3 were substantially decreased in cells treated for
7 2 hw i t h1 0a n d2 5 μM piceatannol (Figure 2(c)). Other
apoptosis marker changes induced by piceatannol included
cleavage of matured 62-kD AIF to its 57-kD product [33]
and increase in total cytochrome c (Figure 2(c)). Further
analysis implicated DNA damage as a molecular antecedent
for piceatannol-induced apoptosis as phosphorylation of
Ser139 in histone H2AX, a marker for global DNA damage
[34–36], showed a marked elevation in DU145 cells treated
with 10 or 25μM piceatannol (Figure 2(d)).
3.3. Piceatannol-Suppressed mTOR Expression, in Concor-
dance with Reduced Levels of eIF4E-BP1 and AKT. To obtain4 ISRN Urology
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Figure 2:EﬀectsofpiceatannoloncellcyclecontrolinLNCaP,DU145,andPC-3CaPcells.Cellsweretreatedwithvaryingconcentrationsof
piceatannol (0,10,and25μM)for72hand changes of cell cycle bypiceatannol were furtheranalyzed. (a)The eﬀectoncellcycle distribution
wasanalyzedbyﬂowcytometry.ThepercentageofcellsinG1,S,andG 2Mphaseswerecalculatedandvaluesareexpressedasmean±SD.Cells
with hypodiploid DNA content (sub-G1) representing fractions undergoing apoptosis were also calculated. (b) Changes on the expression
of various cell cycle regulatory proteins by piceatannol in LNCaP and PC-3 cells. Western blot analysis of cyclins D1 E and CDK6/CDK2
protein expression levels in total cell lysate treated with piceatannol for 72h. (c) Eﬀects of piceatannol treatment on apoptosis-associated
proteins in DU145 cells. Changes in expression of PARP, caspase 3, cytochrome C, and AIF were further analyzed by western blot analysis.
(d) Eﬀects of piceatannol on DNA-damage-associated changes in DU145 cells were further analyzed by determining the changes in the
expression of phosphorylated H2AX using western blot analysis. Actin expression was used as a loading control. The intensity of the speciﬁc
immunoreactive bands was quantiﬁed by densitometry and expressed as a fold diﬀerence against actin.
further information on piceatannol-induced growth arrest,
we tested the possible involvement of mTOR and mTOR-
linked signaling events. A dose-dependent reduction of
mTOR expression occurred in all three CaP cells exposed
to piceatannol, whereas diﬀerential expression of mTOR
among three CaP cells was also observed (Figure 3(a)).
Piceatannol also aﬀected mTOR downstream eﬀectors eIF-
4EandeIF4E-BP1[37,38].Forexample,adecreaseinstateof
phosphorylation in Ser209 of eIF-4E and in Ser65 of eIF4E-
BP1 was observed in DU145 cells (Figure 3(b)), whereas
reduced phosphorylated eIF4E (Ser209) was observed in
LNCaP with undetectable changes on eIF4E-BP1 (Ser65),
following treatment by 25μM piceatannol (Figure 3(b)). In
PC-3 cells, piceatannol caused downregulation of phospho-
rylatedeIF4E-BP1(Ser65)whileslightlyincreasingphospho-
rylated eIF4E (Ser209) (Figure 3(b)). We additionally tested
if piceatannol aﬀected S6 ribosomal protein levels and phos-
phorylation of p70-S6 kinase, both involved in control of
cell proliferation, functioning as mTOR downstream targets
[39, 40]. All three CaP cell lines showed undetectable p70-
S6 kinase (Thr389) (data not shown). However, piceatannol
inhibited p-S6 (Ser235/236) expression in LNCaP and PC-
3 cells (Figure 3(c)). Since AKT is an upstream modulator
and activator of mTOR [41, 42], we analyzed changes in
AKT expression. A dose-dependent suppression of total and
Thr308-phosphorylatedAKTwasfoundinallthreeCaPcells
treated by piceatannol (Figure 3(d)).
4. Discussion
We have investigated the growth suppressive activities of
piceatannol by exposing cultured cells representing diﬀer-
ent stages of CaP, respectively, LNCaP (AD), DU145 and
PC-3 (both AI) to the polyphenol without prior serum
depletion. A dose-dependent inhibition of proliferation and
clonogenicity was observed in all CaP cells tested; PC-
3 cells were more eﬀectively aﬀected using the prolifera-
tion assay (Figure 1), while most signiﬁcant reduction in
colony formation was found in DU145 cells (Figure 1).
These results conﬁrmed and extended the reported growth
control and apoptotic attributes of piceatannol [25, 26]
and suggest that this polyphenol inhibits CaP proliferation
irrespective of cellular dependency on hormones or culture
conditions.
Previously, it has been reported that piceatannol exerts
selectivity and potency against DU145 CaP cells [25]
compared to normal prostate PWR-1E cells [25, 26]a n d
that it induces cell cycle arrest and apoptosis via the
inhibition of CDK activity and activation of the death
receptor/mitochondrial-dependent pathways, respectively
[25,26].Tomorefullygleanitsanti-CaPpotential,wesought
to elucidate further insights into its mechanism of action. In
DU145 cell studies we have found that exposure to piceatan-
nol resulted in (i) PARP and caspase 3 changes (Figure 2(c))
implicating the involvement of caspase-dependent mode of
cell death, (ii) AIF and cytochrome c changes (Figure 2(c))
implicating the involvement of mitochondria-dependent,
caspase-independent mode of cell death, (iii) increased
histone H2AX Ser139 phosphorylation (Figure 2(d)) sug-
gesting coupling between induction of apoptosis with
piceatannol-elicited DNA damage, and (iv) disruption of
mTOR signaling, as evident by downregulation of AKT,
mTOR, and eIF-4E-BP1 protein expression. Furthermore,
suppression of proliferation and diﬀerential downregulation
of AKT/mTOR expression were also found in LNCaP and
PC-3 cells treated with piceatannol. The demonstration that6 ISRN Urology
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Figure 3: Eﬀects of exposure to piceatannol on mTOR and its downstream p-4E-BP1/p-eIF4E and upstream AKT expression in LNCaP,
DU145, and PC-3 cells. Cells were treated with varying concentrations of piceatannol (0, 10, and 25μM) for 72h, and immunoblot analysis
wasusedtoassessthechangesinproteinlevelsof(a)mTOR,(b)phosphorylatedp-4E-BP1(Ser65),andp-eIF4E(Ser209)(c)phosphorylated
p-S6 ribosomal protein (Ser235/236), (d) total and phosphorylated AKT (Thr308). In each case, actin was used as a loading control. The
intensity of the speciﬁc immunoreactive bands was densitometrically quantiﬁed and expressed as a fold diﬀerence against actin.
piceatannol induces marked reduction in AKT and mTOR
levels in CaP cells (Figure 3) is signiﬁcant and suggests a
novel mechanism by which this polyphenol acts as a dietary
agent for chemoprevention of CaP. Conceivably, piceatannol
may aﬀect CaP cell proliferation by targeting protein synthe-
sis, mediated in part through the AKT/mTOR/eIF-4E-BP1
pathway. AKT is robustly activated in various cancers and
the AKT signaling cascade is well integrated with growth-
factor-mediatedpathwaysinCaP,havingimplicationsinCaP
survival and development [41, 43]. There is a wealth of
evidence in support of the profound role mTOR plays in
CaP. For example, inhibitors of the mTOR pathway have
been shown to restrict CaP cell proliferation. Furthermore,
suppressionofmTORbyrapamycineﬀectivelyreversesAKT-
dependentprostaticintraepithelialneoplasia(PIN)inmouse
model studies [43].
Since mTOR also acts as a molecular sensor and enforcer
of cellular responses to changes in growth factors and
nutrient status of the cell, by turning on the synthesis of
proteins including those critically involved in the control of
growth and cell cycle phase transition [44, 45], we assayed
changes in one of the downstream translational eﬀectors
of mTOR, eIF-4E, and eIF-4E-BP1 known to be involved
in mRNA assembly into productive initiation complexes in
eukaryotic protein synthesis. Both were found to be modu-
latedbypiceatannol,suggestingthatthisdietaryagentactsbyISRN Urology 7
Proposed mechanism of action of piceatannol
AIF
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Caspase 3
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Figure 4: A model mechanism on the ability of piceatannol to
induce apoptosis and suppress cell proliferation in CaP cells is
proposed. (a) For induction of apoptosis, the eﬀects of piceatannol
is postulated to occur secondary to DNA damage accompanied by
increased phosphorylation of H2AX at Ser139, which facilitate and
culminate in the cleavage of caspase 3 and AIF. (b) for suppression
of proliferation, piceatannol is proposed to inhibit the AKT/mTOR
signaling pathway resulting in suppression of CaP cell proliferation
and survival.
regulatingthedynamicsofinterplaybetweentheengagement
and sequestration of initiation factors with a dominant role
in mRNA binding and translation and in the regulation of
speciﬁc mRNA recruitment from mRNA-ribonucleoprotein
particles for participation in protein synthesis and growth
control. One aspect of our current hypothesis is that the
mTOR signaling pathway is a potential target of piceatannol
and that CaP showing propensity for activation by mTOR
might be selectively responsive to treatment by piceatannol.
Figure 4 depicts the proposed anti-CaP mechanism(s) of
piceatannol.
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